Bristol-Myers Squibb to Acquire Celgene Corporation
NEW YORK & SUMMIT, N.J. — In a deal worth $74 billion, Bristol-Myers Squibb announced today its plans to acquire Celgene Corporation. The transaction, according to Bristol-Myers, will create a leading focused specialty biopharma company well positioned to address the needs of patients with cancer, inflammatory and immunologic disease and cardiovascular disease through high-value innovative medicines and leading scientific capabilities. Together, the combined new entity will manufacture nine products that Bristol-Myers estimates will generate $1 billion in yearly sales.
What does this transaction mean for the strategic options for your healthcare business?
Contact Paragon Ventures for more information. https://www.paragonventures.com 800-719-1555
Paragon Ventures is a leading specialist in strategic transactions including the merger and acquisition of private mid-market healthcare companies. Celebrating its 25th year in business, Paragon Ventures has advised thousands of healthcare business owners and successfully closed over 225 strategic healthcare transactions.
